NCT04083365 - Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

November 30, 2022

Study Completion Date

August 31, 2025

Conditions

RECTAL CANCER

Interventions

DRUG

Capecitabine

chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks

DRUG

Radiotherapy

5040 cGy radiotherapy for 5 days per week for 5 weeks

DRUG

Durvalumab

One week after the end of CT/RT patients will be treated with 1500 mg IV Q4W durvalumab for 3 administrations

Trial Locations (1)

RECRUITING

Ospedale Degli Infermi Uo Oncologia, Faenza